Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human (FiH) Study of IK-595, an Oral Dual MEK/RAF Inhibitor, in Patients With RAS-or RAF-altered Advanced Solid Tumors

NCT06270082 is registered in ClinicalTrials.gov with Ikena Oncology as lead sponsor.

NCT NCT06270082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06270082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human (FiH) Study of IK-595, an Oral Dual MEK/RAF Inhibitor, in Patients With RAS-or RAF-altered Advanced Solid Tumors
Lead sponsor
Ikena Oncology
Phase
Phase 1
Overall status
Terminated
Start date
December 18, 2023
Completion date
September 8, 2025
Enrollment
75 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

braf gene mutation, colorectal cancer, craf gene mutation, gliomas, malignant, malignant melanoma, non-small cell lung carcinoma, pancreatic cancer, ras (kras or nras) gene mutation, solid tumor, adult, thyroid carcinoma